A Long-Term Follow-Up Study of Participants Treated with A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
Launched by A2 BIOTHERAPEUTICS INC. · Mar 18, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This is a long-term follow-up study designed to evaluate delayed safety events and long-term efficacy of A2 Bio GT products for participants who received any amount of A2 Bio GT products in a previous interventional study. No further interventional treatment is administered in this study.
Participants will enroll in this long-term follow-up study upon completion of 2 years of follow-up in the assigned interventional study in which they received treatment. Participants will be followed for up to 15 years after administration of A2 Bio GT product. This study will collect long-term safety and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
- • 2. Able to provide written informed consent for this long-term follow-up study
- • 3. Able to comply with study requirements
- Exclusion Criteria:
- • 1. There are no specific exclusion criteria for this study
Trial Officials
Eric Ng, MD
Study Director
A2 Biotherapeutics
About A2 Biotherapeutics Inc.
a2 Biotherapeutics Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for patients with unmet medical needs. Leveraging advanced protein engineering and proprietary technologies, the company aims to create targeted biologics that enhance the efficacy and safety of treatment across various disease modalities. Committed to scientific excellence and patient-centric approaches, a2 Biotherapeutics is dedicated to advancing its clinical programs and contributing to the future of medicine through groundbreaking research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
